VOR Vor Bio Inc.: Price-to-Projected Revenue Ratio

Brandmark of Vor Biopharma Inc. (VOR)

The forward price-to-sales ratio reflects market expectations, where the level of represents the current value. This trend is supported by the authority of Vor Biopharma Inc. (VOR) in oncohematology and confidence in their bone marrow protection methods. Profit potential is based on the commercialization of modified stem cells, while growth prospects are linked to the implementation of technologies that enable aggressive treatment without damaging healthy tissues.

VOR (vorbio.com) Forward Price to Sales history from 07/04/2022 to 11/13/2026

Analytical breakdowns for Vor Biopharma Inc.

- market price and analyst price targets:
Price Chart Vor Biopharma|VOR - Average Forecast Price
- company stock capitalization data:
Market Value Vor Bio Inc.|VOR - Value Adjusted for Debt and Cash
- book value of equity indicators:
Accounting Value per Share Vor Biopharma|VOR - Accounting Value of Company|Market Capitalization to Book Value Ratio vorbio.com|VOR - Aggregate Company Assets
- debt and solvency information:
Total Debt to Capital Vor Biopharma Inc.|VOR - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Vor Biopharma Inc.|VOR - Company Cumulative Debt|Debt to Book Capitalization Ratio Vor Bio Inc.|VOR - Long-Term Liabilities|Company Short-Term Debts Vor Biopharma|Quick Ratio vorbio.com
- net income and valuation multiples indicators:
VOR - Net Profit|Expected Profit Vor Biopharma Inc.|VOR - Company Value to Net Income|Future Price to Earnings Vor Bio|VOR - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Vor Bio Inc.|VOR - Operating profit EBITDA|Net earnings per share for the last 12 months Vor Biopharma|VOR - Earnings per share for the trailing year|Quarterly EPS earnings growth vorbio.com|VOR - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Vor Biopharma Inc.
- company sales and revenue statistics:
VOR - Company Sales Volume|Projected Sales Volume Vor Biopharma|VOR - Market Cap to Revenue|Forward Price-to-Revenue Multiple Vor Bio Inc.
Initial company analysis:VOR (Vor Biopharma)
Product sample of Vor Biopharma Inc.

To construct a defensive portfolio, fundamental screening requires an analysis of market capitalization relative to projected revenue, which allows investors to filter out short-term market noise from the actual business value. In the case of Vor Biopharma Inc. (VOR), the product cycle's independence from macroeconomic factors makes the forward P/S trend a key indicator of the fair valuation of investments in innovative developments, reflecting the asset's long-term attractiveness.

Direct competitors

Price-to-Projected Revenue Ratio TG Therapeutics TGTX|Arcellx Inc (ACLX) - Market Cap to Future Revenue Ratio|IRON - Price-to-Projected Revenue Ratio|Forward Price to Sales SNDX (Syndax Corp)|KURA (Kura Oncology, Inc.) - Forward Price-to-Revenue Multiple|adctherapeutics.com - Forward Price to Sales|FHTX (Foghorn Therapeutics, Inc.) - Forward P/S Multiple|Price-to-Projected Revenue Ratio NKTX|Forward P/S Multiple COEP|Market Cap to Expected Sales Ratio Actinium Corp|Price-to-Projected Revenue Ratio Estrella Immunopharma ESLA|CASI Pharmaceuticals Inc. (CASI) - Market Cap to Future Revenue Ratio|MRKR - Price-to-Projected Revenue Ratio|Future Price to Revenue INAB|ERNA: Forward P/S Multiple|GT Biopharma Corporation - Forward Price to Sales|APTO (Aptose Biosciences Inc) - Forward P/S Multiple|Forward P/S Multiple biopathholdings.com|Price-to-Projected Revenue Ratio MEI Pharma (MEIP)|VINC (vincerx.com) - Forward Price to Sales